Putnam Investments LLC increased its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 45.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,504 shares of the company’s stock after purchasing an additional 26,518 shares during the period. Putnam Investments LLC’s holdings in Zoetis were worth $14,065,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Aspire Private Capital LLC purchased a new stake in Zoetis in the 1st quarter valued at $15,019,213,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the last quarter. VitalStone Financial LLC purchased a new stake in Zoetis in the 1st quarter valued at $37,000. Evermay Wealth Management LLC raised its position in Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the last quarter. Finally, Worth Asset Management LLC purchased a new stake in Zoetis in the 1st quarter valued at $26,000. 89.47% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. HSBC assumed coverage on Zoetis in a research report on Wednesday, September 6th. They issued a “buy” rating and a $230.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $205.00 target price on shares of Zoetis in a research report on Tuesday. The Goldman Sachs Group raised their target price on Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. StockNews.com raised Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, Piper Sandler raised their target price on Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Monday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $225.13.
Zoetis Trading Down 1.4 %
Shares of ZTS opened at $180.14 on Friday. The business has a 50-day moving average of $183.39 and a 200 day moving average of $175.07. Zoetis Inc. has a fifty-two week low of $124.15 and a fifty-two week high of $194.99. The firm has a market cap of $82.92 billion, a P/E ratio of 37.84, a price-to-earnings-growth ratio of 2.94 and a beta of 0.78. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.97 and a current ratio of 3.50.
Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.10. Zoetis had a return on equity of 52.02% and a net margin of 26.92%. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.16 billion. During the same quarter last year, the firm posted $1.20 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc. will post 5.42 EPS for the current year.
Insiders Place Their Bets
In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total value of $2,339,610.00. Following the completion of the transaction, the chief executive officer now owns 56,843 shares in the company, valued at approximately $10,230,034.71. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Zoetis news, EVP Robert J. Polzer sold 1,179 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $189.94, for a total value of $223,939.26. Following the completion of the transaction, the executive vice president now owns 2,353 shares in the company, valued at approximately $446,928.82. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total value of $2,339,610.00. Following the completion of the transaction, the chief executive officer now owns 56,843 shares of the company’s stock, valued at approximately $10,230,034.71. The disclosure for this sale can be found here. Insiders sold a total of 15,102 shares of company stock worth $2,741,661 in the last quarter. 0.12% of the stock is owned by company insiders.
About Zoetis
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- Investing in Commodities: What Are They? How to Invest in Them
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Reasons Price Weakness Is a Buying Opportunity For Lennar
- What to Know About Investing in Penny Stocks
- Name A Better Trio Than These Underrated High Potential Stocks
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
